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bodies and a consideration of prodromal
diagnosis
Paul C Donaghy* and Ian G McKeithAbstract
Dementia with Lewy bodies (DLB) is the second most common type of degenerative dementia following
Alzheimer’s disease (AD). DLB is clinically and pathologically related to Parkinson's disease (PD) and PD dementia,
and the three disorders can be viewed as existing on a spectrum of Lewy body disease. In recent years there has
been a concerted effort to establish the phenotypes of AD and PD in the prodromal phase (before the respective
syndromes of cognitive and motor impairment are expressed). Evidence for the prodromal presentation of DLB is
also emerging. This paper briefly reviews what is known about the clinical presentation of prodromal DLB before
discussing the pathology of Lewy body disease and how this relates to potential biomarkers of prodromal DLB. The
presenting features of DLB can be broadly placed in three categories: cognitive impairment (particularly
nonamnestic cognitive impairments), behavioural/psychiatric phenomena (for example, hallucinations, rapid eye
movement sleep behaviour disorder (RBD)) and physical symptoms (for example, parkinsonism, decreased sense of
smell, autonomic dysfunction). Some noncognitive symptoms such as constipation, RBD, hyposmia and postural
dizziness can predate the onset of memory impairment by several years in DLB. Pathological studies of Lewy body
disease have found that the earliest sites of involvement are the olfactory bulb, the dorsal motor nucleus of the
vagal nerve, the peripheral autonomic nervous system, including the enteric nervous system, and the brainstem.
Some of the most promising early markers for DLB include the presence of RBD, autonomic dysfunction or
hyposmia, 123I-metaiodobenzylguanidine cardiac scintigraphy, measures of substantia nigra pathology and skin
biopsy for α-synuclein in peripheral autonomic nerves. In the absence of disease-modifying therapies, the diagnosis
of prodromal DLB is of limited use in the clinic. That said, knowledge of the prodromal development of DLB could
help clinicians identify cases of DLB where the diagnosis is uncertain. Prodromal diagnosis is of great importance in
research, where identifying Lewy body disease at an earlier stage may allow researchers to investigate the initial
phases of dementia pathophysiology, develop treatments designed to interrupt the development of the dementia
syndrome and accurately identify the patients most likely to benefit from these treatments.Introduction
Dementia with Lewy bodies (DLB) is the second most
common type of degenerative dementia following Alzhei-
mer’s disease (AD). DLB accounts for around 4.2% of all
dementia diagnosed in the community, and 7.5% of those
under secondary care [1]. The characteristic features of
DLB are spontaneous parkinsonism, recurrent visual
hallucinations, fluctuating cognition, rapid eye movement
sleep behaviour disorder (RBD), severe sensitivity to* Correspondence: paul.donaghy@ncl.ac.uk
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2014antipsychotic medications and reduction in striatal dopa-
mine transporters on single photon emission computed
tomography (SPECT) or positron emission tomography
(PET) (Figure 1) [2]. The pattern of neuropsychological
deficits seen in DLB is different to those in AD, with less
marked memory impairment and more severe impair-
ments of visuospatial, attentional and frontal-executive
function [3].
The clinical features of DLB and Parkinson’s disease
dementia (PDD) are similar [2,4]. Based on international
consensus, DLB is diagnosed when cognitive impairment
precedes parkinsonism or begins within a year of parkinsonism.d Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Diagnostic criteria for dementia with Lewy bodies.
CT, computed tomography; DLB, dementia with Lewy bodies; EEG,
electroencephalogram; MRI, magnetic resonance imaging; MIBG,
metaiodobenzylguanidine; PET, positron emission tomography; REM,
rapid eye movement; SPECT, single photon emission computed
tomography. Adapted from [2].
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impairment by more than 1 year (Figure 2) [2]. DLB and
PDD are now recognised in the Diagnostic and Statistical
Manual of Mental Disorders, where they are respectively
coded as ‘Major and Mild Neurocognitive Disorder with
Lewy Bodies’ and as ‘Major and Mild Neurocognitive
Disorder due to Parkinson’s Disease’ [5].
As with Parkinson’s disease (PD) and PDD, the main
pathological lesions seen in DLB are Lewy bodies (LBs)
and Lewy neurites, both containing α-synuclein (αSyn)
[6]. The pattern of distribution of LB pathology in DLB,
PD and PDD as seen at end stage is very similar, al-
though cortical involvement may occur earlier in DLB
and brainstem involvement may be minimal [7-9]. The
three disorders can be viewed as existing on a spectrumof LB disease [10], suggesting that studies of symptom
development and pathology in PD, although not identi-
cal, are probably highly relevant to any consideration of
the early stages of DLB.
In recent years there has been a concerted effort to es-
tablish the phenotypes of AD and PD in the prodromal
phase, which is defined as the period between the onset
of the earliest symptoms and the development of the full
clinical syndrome. Evidence of the prodromal presenta-
tion of DLB is also emerging [11]. Criteria for the clin-
ical diagnosis of DLB have high specificity but low
sensitivity [12]. In the move towards earlier diagnosis,
biomarkers of LB disease may be necessary to optimise
diagnostic accuracy. This paper briefly considers what is
known about the clinical presentation of prodromal DLB
before discussing the pathology of LB disease and how
this relates to potential biomarkers of prodromal DLB.
The paper will then discuss how this knowledge can be
applied to current clinical and research practice.
Symptoms of prodromal dementia with Lewy bodies
The presenting features of DLB can be broadly placed in
three categories (Figure 3): cognitive impairment; behav-
ioural/psychiatric phenomena; and physical symptoms.
Cognitive impairment
Mild cognitive impairment (MCI) is conceived as a state
intermediate between normal cognitive function and
dementia [13]. People with MCI are at increased risk of
developing dementia [14], leading to MCI being consid-
ered a prodromal phase of dementia [15]. A proportion
of MCI cases that convert to dementia may develop
DLB, although rates have varied from around 5% to
around 25% across different studies [16-19]. Some of this
variation is likely to be due to recruitment criteria for
the studies; for example, amnestic MCI largely from pri-
mary care, 5.6% DLB [17]; MCI from a tertiary referral
centre, 28.4% DLB [18]. DLB can be preceded by amnes-
tic or nonamnestic cognitive impairment, although cases
involving nonmemory domains (that is, attention/execu-
tive, visuospatial or language) are more likely to progress
to DLB than single-domain amnestic MCI [19,20].
Fluctuating attention and cognition is a core feature of
DLB [2], but evidence so far suggests that fluctuations
are the least common core symptom in the prodromal
phase (present in 2/7 cases [21] and 3/9 cases [22] in
two longitudinal studies). Delirium and transient distur-
bances of consciousness, however, are reported as pro-
dromal features of DLB and may represent the earliest
manifestations of cognitive fluctuation [23].
Behavioural/psychiatric phenomena
Importantly, DLB may initially present with noncogni-
tive symptoms such as visual hallucinations, depression
Figure 2 Nomenclature of Lewy body diseases. Parkinson’s disease dementia is diagnosed when cognitive impairment develops a year or
more after the onset of parkinsonism. Dementia with Lewy bodies is diagnosed when cognitive symptoms appear without parkinsonism or less
than 1 year after the onset of parkinsonism.
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enactment of dreams (for example, punching, kicking,
shouting out) that often results in injury. Longitudinal
studies of RBD have shown that up to 93% of cases go
on to develop a synucleinopathy – PD, PDD, DLB or? Non-amnestic cognitive impairments
? Cognitive fluctuations (less common)
Cognitive
? REM sleep behaviour disorder
? Visual hallucinations
? Depression
? Delirium
Psychiatric / behavioural
? Parkinsonism
? Hyposmia
? Constipation
? Orthostatic hypotension
Physical
Figure 3 Examples of presenting symptoms of dementia with
Lewy bodies. REM, rapid eye movement.multiple system atrophy, a clinically and pathologically
distinct non-LB synucleinopathy [25] – if followed up
for a sufficient number of years [26-28].
Retrospective studies have found that visual hallucina-
tions and RBD can be present in around one-half of
DLB cases prior to or around the onset of memory loss
[24,29,30]. Anxiety and depression were present in
around one-quarter of patients [24,29]. Retrospective
case–control studies have found that a history of depres-
sion [31] or delirium [23] prior to the diagnosis of
dementia is more common in DLB than AD, although
both delirium and depression are probably too common
in the normal older person to be useful biomarkers in
isolation.
Physical symptoms
Parkinsonism is a core feature of DLB, and may be a
presenting symptom in around one-quarter of patients
[24]. αSyn deposition in the olfactory bulb, brainstem
and peripheral nervous system in LB disorders is associ-
ated with a variety of physical symptoms, such as de-
creased sense of smell (hyposmia), constipation, orthostatic
dizziness and increased salivation [24].
Some noncognitive symptoms of DLB such as consti-
pation, hyposmia and postural dizziness can predate the
onset of memory impairment by years in DLB [29]. In
the earliest clinical phase of DLB, patients may therefore
be expected to present with one or, more probably, a
combination of these symptoms in mild form. Based on
the presence of these symptoms one could suppose that
a person has prodromal LB disease, even in the absence
of cognitive dysfunction, but given that these are
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selves likely to be very nonspecific predictors. Given this
nonspecificity, a combination of several symptoms along
with other biomarkers may be necessary to identify
those with prodromal DLB.
Neuropathology of dementia with Lewy bodies
Prior to any discussion of the probable biomarkers of
prodromal DLB, the temporal development of LB path-
ology must be considered. Much of the work on the
pathology of LB disease comes from research in PD. Just
over a decade ago, Braak and colleagues proposed a sta-
ging system for Lewy pathology in PD [32]. In a sample
of brains from PD patients and asymptomatic individ-
uals with LB disease, they found that all could be
classified into one of six stages of disease development.
At the earliest stage (stage 1), LB pathology was confined
to the dorsal motor nucleus of cranial nerves IX/X and
the intermediate reticular zone of the medulla. Over the
subsequent stages, LB pathology ascended sequentially
through the pons, midbrain and subcortical structures to
finally affect the neocortex itself in stages 5 and 6
(Figure 4). A key feature of Braak staging was that the
sequential ascent of LB pathology from the brainstem to
the neocortex was common to all cases – that is, the
cortex was not involved in every case; but where the cor-
tex was affected, so were lower structures such as the
limbic system and brainstem. Others have observed that
LB pathology does not necessarily follow this pattern of
distribution, particularly when cases are sampled from
the general population, in which LB pathology can beFigure 4 Progression of Lewy body pathology. Schematic diagram
of the pattern of alpha-synuclein deposition as hypothesised by Braak
and colleagues [32]. Deposition is first seen in the peripheral autonomic
nervous system, including the enteric nervous system. This is then
followed by deposition in the brainstem, ascending to the limbic
system and, finally, the neocortex. Illustration from [88], available under
creative commons license.found in higher centres such as the neocortex, despite
sparing of lower regions [7,33-35]. Nevertheless, it is
clear that some structures are particularly susceptible to
LB pathology and may potentially act as sentinels for the
development of LB disease: the olfactory bulb [7], the
dorsal motor nucleus of the vagal nerve and other brain-
stem structures [32] and the peripheral autonomic ner-
vous system [36,37], including the enteric nervous
system [38].
The pattern of deposition of Lewy pathology in DLB
cases seen at autopsy is similar to that of PD/PDD [7,8].
Dementia is the clinical expression of widespread and
relatively advanced brain disease. Unsurprisingly, then,
the majority of DLB cases are found to have an advanced
Braak stage, with cortical involvement [7,8]. The actual
amount of cortical LB pathology does not necessarily
correlate with clinical dementia severity [39], and signifi-
cant cortical pathology can occur in the absence of clin-
ical symptoms [33,40]. One explanation for this is that
LBs do not directly cause cell dysfunction and death.
Presynaptic accumulation of αSyn and resultant synaptic
dysfunction has been put forward as a causative factor of
neurodegeneration in LB disease but, like LB deposition,
this cannot yet be measured in vivo [41].
Postmortem examination of brains from people who
suffered from DLB is informative to a degree about the
pathology of the later stages of disease, but less so about
the earlier stages of disease development. Findings from
studies of early PD and LB disease without any clinical
symptoms (incidental LB disease) may be used to hy-
pothesise about the early pathological development of
DLB.
Incidental LB disease with cortical involvement has
been suggested to be more likely to progress to DLB
than PD [33]. If so, the profile of structural and func-
tional brain changes that can be detected in vivo during
the prodromal phases of LB disease will probably also
vary between DLB and PD, reflecting differences in the
underlying pathology. Some pathological differences be-
tween DLB and PDD have been identified [42]. DLB is
associated with higher amyloid plaque deposition in the
striatum [43,44], more frequent αSyn deposition in the
CA2/3 area of the hippocampus [45] and significantly
higher 5-HT1A receptor density in the frontal cortex
[46]. Compared with PD, DLB demonstrates less marked
cell loss in the substantia nigra, and a relative lack of D2
receptor upregulation in the striatum [47].
Although LB pathology is the pathological hallmark of
DLB, other types of pathology may interact with LB path-
ology, or may potentially mimic the DLB phenotype in the
absence of significant LB pathology. In community-based
cohorts, dementia is most often associated with mixed
pathology including AD, vascular and LB pathology [48].
MCI in PD is associated with heterogeneous pathology
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and tau) is frequently found in DLB at postmortem
[49,50]. The importance of AD pathology in DLB is not
yet clear. In amyloid PET imaging studies, LB disease
groups have lower mean amyloid ligand binding than AD
groups. Many cases have normal levels of amyloid bind-
ing, although amyloid deposition is more common in DLB
than PDD and is relatively rare in PD, suggesting that Aβ
may be associated with an increased risk of dementia in
LB disease [51]. The presence of AD pathology may re-
duce the likelihood of expression of the typical DLB
phenotype [52,53]. In some cases of LB disease, LBs are
predominantly confined to the amygdala [54]. This pattern
of deposition is common in AD, and may represent a dif-
ferent clinicopathologic process to PD/PDD/DLB [7,55].
A hypothetical biomarker profile of prodromal
dementia with Lewy bodies
Jack and colleagues put forward a model of dynamic bio-
markers for AD, with markers of Aβ deposition sequen-
tially followed by markers of tau-mediated neuronal
injury and dysfunction, changes in brain structure, ab-
normalities in tests of memory and, finally, a decline in
day-to-day function [56]. This hypothesis has been criti-
cised due to emerging evidence against the amyloid cas-
cade hypothesis [57]. Nevertheless, the idea of a processTime
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Figure 5 Hypothetical timelines of biomarker development. (A) Bioma
mirrors that proposed by Jack and colleagues in Alzheimer’s disease [56]. The
deposition (for example, from skin biopsy). αSyn deposition probably decreas
be followed by markers of cell damage or death (for example, loss of dopami
tomography or positron emission tomography) and then clinical symptoms/s
this hypothetical representation, αSyn deposition, cell damage and loss and t
prior to the development of αSyn deposition in the neocortex.beginning with abnormal protein deposition followed by
cell damage or death and then loss of function is a useful
conceptual base from which to consider the likely devel-
opment of biomarkers in DLB (Figure 5A). DLB is asso-
ciated with a relative lack of structural brain changes
compared with AD [58] and structural change can be
presumed to be less likely and therefore harder to detect
in the earliest stages of disease. The additional effects of
Alzheimer pathology may well operate to a greater or
lesser extent in many subjects but these have not been
incorporated into the schematic.
The process of abnormal protein deposition–cell dam-
age–functional decline will occur at different times in
different areas (Figure 5B), with both the peripheral and
central nervous systems involved early in DLB. For ex-
ample, measureable loss of function may occur in the ol-
factory system before significant protein deposition has
occurred in higher cortical areas. The following para-
graphs examine possible biomarkers of protein depos-
ition, cell damage and functional decline to assess their
potential usefulness in prodromal DLB in relation to
what is known about the pathology of LB disease.
Biomarkers of protein deposition
In vivo measurement of Aβ, the putative pathological
hallmark of AD, is possible with cerebrospinal fluid AβSyn deposition
ell damage and dysfunction
linical symptoms/signs
Olfactory bulb
Neocortex
rker development in dementia with Lewy bodies (DLB). This hypothesis
first biomarkers of DLB will be markers of alpha-synuclein (αSyn)
es later in the disease process following cell death [40]. This would then
ne transporters in the striatum on single photon emission computed
igns (for example, parkinsonism). (B) Biomarkers in two different sites. In
he development of symptoms (hyposmia) all occur in the olfactory bulb
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available to image αSyn in vivo, although some are in de-
velopment [59]. Several studies have found reduced
cerebrospinal fluid αSyn in established DLB, although
other studies have found no such differences [60]. This
heterogeneity of results may reflect methodological dif-
ferences in the measurement of αSyn, or cerebrospinal
fluid contamination with red blood cells, which are rela-
tively rich in αSyn [60]. The utility of blood and cerebro-
spinal fluid biomarkers in the diagnosis of DLB remains
unresolved. There has been no research into the use of
such markers in the prodromal stage of DLB.
Some of the earliest sites of LB deposition include the
olfactory bulb [7,32] and the enteric nervous system
[38,61]. Biopsies from these sites are a possible route to
detect αSyn deposition in vivo [62,63] with potential for
early diagnosis, although the invasiveness of these tech-
niques could limit their application [64].
More recently, Wang and colleagues used a new tech-
nique to measure the proportion of peripheral auto-
nomic nerve fibres containing αSyn in skin biopsies [65].
In a sample of patients with PD and controls, αSyn was
detected in all subjects but rates in the PD group were
markedly higher [65]. The difference was less marked in
those with mild disease, although it remained significant.
The sampling and processing techniques used in this
study were more sensitive than previous techniques, de-
tecting αSyn even in controls, suggesting a threshold ra-
ther than absolute biomarker potential.
Biomarkers of cell death or dysfunction
123I-metaiodobenzylguanidine cardiac scintigraphy
Specialised imaging techniques are already in use to detect
cell death and dysfunction in neural systems particularly
vulnerable in LB disease. Cardiac 123I-metaiodobenzylgua-
nidine (MIBG) scintigraphy uses a noradrenaline analogue
to identify presynaptic sympathetic nerve terminals in the
heart. This technique can detect cardiac sympathetic de-
nervation that is associated with LB disorders.
In one study, seven asymptomatic individuals had ab-
dominal or pelvic autonomic plexuses removed during
surgery (generally for oncologic disease) and examined
for the presence of αSyn. Later, the patients underwent
123I-MIBG cardiac scintigraphy and a striatal dopamine
transporter scan. All four αSyn-positive patients had an
abnormal cardiac MIBG scan, compared with none of
the αSyn-negative patients. Conversely, only one of four
αSyn-positive patients and no αSyn-negative patients
had a positive 123I-N-ω-fluoropropyl-2β-carbomethoxy-
3β-(4-iodophenyl)nortropane SPECT scan [37]. Two
cases of DLB have been reported with abnormal 123I-
MIBG cardiac scintigraphy during the MCI phase of the
illness [66]. However, cardiac MIBG uptake can be ab-
normal in congestive cardiac failure, ischaemic heartdisease and diabetic autonomic neuropathy, potentially
limiting its usefulness, particularly in older people [67].
Biomarkers of substantia nigra pathology
Cell death in the substantia nigra can be assessed by
measuring nigrostriatal dopaminergic innervation of the
striatum using PET or SPECT with a radiolabelled dopa-
mine analogue (N-ω-fluoropropyl-2β-carbomethoxy-3β-
(4-iodophenyl)nortropane) (Figure 6). The substantia
nigra is a relatively early site of LB deposition (stage 3 in
the Braak system) [32] and dopaminergic depletion in
the striatum might be anticipated to be a sensitive indi-
cator of early LB disease. However, three of 27 patients
with MCI followed-up for 3 years developed DLB, and
only one of these had a positive striatal dopamine trans-
porter scan at baseline [68]. Another patient with a posi-
tive scan developed frontotemporal dementia. This
observation is consistent with the late or minimal in-
volvement of brainstem dopaminergic projection neu-
rones in many DLB cases and suggests that the optimal
time point for dopamine transporter imaging may be in
established rather than prodromal disease.
Another marker of substantia nigra pathology is en-
larged hyperechogenicity on ultrasound. Of 1,535 healthy
adults that had baseline substantia nigra ultrasonography
and completed follow up, 11 developed PD. Eight of these
cases had substantia nigra hyperechogenicity, compared
with 18% of the rest of the sample [69]. In an RBD group,
2/43 patients developed DLB. Both had substantia nigra
hyperechogenicity at baseline, and one also had reduced
striatal dopamine transporters on SPECT imaging [70].
Other biomarkers of cell dysfunction or death
Two longitudinal studies following MCI subjects found
that DLB subjects had heterogeneous patterns of cortical
hypometabolism on 18 F-fluorodeoxyglucose PET during
the MCI phase, but not the occipital hypometabolism
that best differentiates established DLB from AD [71,72].
Fujishiro and colleagues followed a case series of 10
nondemented patients that had attended their memory
clinic and were found to have baseline occipital hypome-
tabolism [73]. Four converted to probable DLB, and one
to possible DLB; all of these had baseline RBD.
Cortical atrophy is less marked in DLB compared with
AD, and therefore is unlikely to be prominent early in
the disease [58]. In three autopsy-confirmed DLB pa-
tients that had serial magnetic resonance imaging during
the MCI phase, hippocampal volumes and rates of hip-
pocampal atrophy were within the range of cognitively
normal subjects [21].
Clinical biomarkers of functional decline
In AD, loss of function – detected by neuropsychological
tests or reported by the patient – is expected to appear
DLBADControl
A: Dopamine transporter imaging (123I-FP-CIT SPECT)
B: Blood flow imaging (99mTc-HMPAO SPECT)
DLBADControl
Figure 6 Examples of imaging abnormalities in dementia with Lewy bodies. (A) Dopamine transporter imaging. Both the control and
Alzheimer’s disease (AD) subjects display normal dopamine transporter levels in the striatum. The dementia with Lewy bodies (DLB) subject
displays reduced uptake in the putamen bilaterally, reflecting nigrostriatal degeneration. (B) Cerebral blood flow imaging. The AD subject shows
decreased perfusion compared with control, particularly in the left temporal lobe. The DLB subject also exhibits perfusion deficits, but these are
largely confined to posterior regions including the occipital lobes. FP-CIT, N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane;
HMPAO, exametazime; SPECT, single photon emission computed tomography.
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age and structural change. Due to the specific topo-
graphical development of LB pathology, loss of function
in structures affected early in the disease can actually
precede the earliest pathological changes in other brain
areas (Figure 5B). Damage to the olfactory bulb, the en-
teric nervous system and midbrain nuclei can lead to an-
osmia, constipation and RBD, respectively. All of these
symptoms have been reported to occur several years be-
fore the onset of memory impairment in PD [74] and
DLB [29,30]. However, since DLB has an older age of
onset than PD, ‘normal’ subjects will be more likely to
have symptoms such as constipation, minor motor ab-
normalities and postural hypotension. This may decrease
the specificity of individual clinical biomarkers in pro-
dromal DLB, which may best be described by a pattern
of symptoms accumulating over time.
There has been little investigation of clinical biomarkers
in MCI cohorts followed up for DLB. One group has in-
tensively studied a cohort with RBD, a population at risk
of subsequent development of full-blown LB disease. They
found that those with RBD who developed PD or DLB
had evidence at baseline of greater postural fall in bloodpressure [75], minor motor abnormalities [76] and worse
colour vision and olfactory function [77], although not
electrocardiographic measures of cardiac autonomic dys-
function [78]. In PD, large cohorts have failed to link later
development of PD with baseline orthostatic hypotension
or heart-rate variability [36]. The 13C-breath test is a
measure of delayed gastric emptying that is abnormal even
in early PD [79] and could be a marker of prodromal LB
disease, although this has not yet been investigated.
Discovering the true clinical accuracy of symptoms
and biomarkers in identifying prodromal DLB is only
achievable through further prospective research to deter-
mine whether a cumulative risk score or profile could
distinguish prodromal LB disease cases from normal
controls and other dementia prodromes.
A staged approach may be necessary, beginning with
bedside screening to identify those that may have LB dis-
ease by assessing for markers of functional decline – using
symptom questionnaires, cognitive tests and simple clin-
ical biomarkers (for example, biomarkers for hyposmia).
In the second stage, those with a profile suggestive of LB
disease would undergo tests with greater specificity, iden-
tifying death or dysfunction of cell groups affected by LB
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might include cardiac MIBG scintigraphy, striatal dopa-
mine transporter imaging or a biopsy for the presence of
αSyn (Figure 7). The aim of such a process would be to
identify cases of prodromal DLB with high sensitivity and
specificity, whilst minimising the use of invasive and ex-
pensive tests.
Evidence supporting the presence of LB disease may
need to be weighed against evidence for the presence of
other diseases such as AD. However, amyloid deposition
is often seen in DLB [51], and DLB can develop from
amnestic MCI [17]. The presence of amnestic MCI and
a positive amyloid PET scan, sufficient for a diagnosis of
‘prodromal AD’ or of ‘MCI due to AD – intermediate
likelihood’ [80,81], is therefore also consistent with pro-
dromal DLB.
Issues in prodromal dementia with Lewy bodies
research
Methodological issues
Research into prodromal DLB is still in its early phase.
There are some difficulties in studying an entity that has
not yet been clearly defined. Retrospective studies of pa-
tients with DLB are helpful for assessing symptom devel-
opment, but these may be susceptible to recall bias andFigure 7 Hypothetical algorithm for the identification of prodromal L
markers of functional decline – symptom questionnaires, cognitive tests an
In the second stage, those with a profile suggestive of Lewy body (LB) dise
dysfunction of cell groups affected by LB pathology, or the presence of alp
zylguanidine (MIBG) scintigraphy, measures of substantia nigra pathology, s
for the presence of αSyn. FP-CIT, N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-are of limited use in assessing the real clinical utility of
biomarkers of prodromal DLB. Longitudinal studies are
needed for this, but existing longitudinal studies of unse-
lected MCI groups generally have relatively small num-
bers of patients that convert to DLB, making such
research prohibitively expensive and limiting the conclu-
sions that can be drawn and generalised.
To ameliorate this problem, longitudinal studies need to
select at-risk groups. Cohorts of RBD patients are already
being investigated in this way [82]. Corresponding cohorts
could also be selected based on the presence of other
symptoms known to be associated with LB disease, such
as hallucinations, parkinsonism or fluctuations, or the
presence of nonamnestic cognitive impairments. Examin-
ing biomarker and symptom profiles over time in such
groups will greatly increase our knowledge of prodromal
DLB. In a virtuous cycle, such research will help to refine
criteria for identifying at risk groups for subsequent
studies.
One must keep in mind that groups with early devel-
opment of symptoms such as RBD are likely to represent
specific subgroups with patterns of disease development
that are not necessarily common to all cases of pro-
dromal DLB [83]. It is clear that some cases of DLB de-
velop core features only later in the disease, if at all [84];ewy body disease. The first stage consists of assessment for simple
d simple clinical biomarkers (for example, biomarkers for hyposmia).
ase would undergo tests with greater specificity, identifying death or
ha-synuclein (αSyn) pathology. This may include cardiac metaiodoben-
uch as ultrasound or striatal dopamine transporter imaging, or biopsy
iodophenyl)nortropane; MCI, mild cognitive impairment.
Note: This article is part of a series on Lewy Body Dementia, edited
by Ian McKeith and James Galvin. Other articles in this series can
be found at http://alzres.com/series/LewyBodyDementia.
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Diagnostic issues
The presence of symptoms associated with LB disease,
such as RBD, hyposmia and autonomic dysfunction,
along with early biomarkers of LB disease may allow the
identification of people who suffer from LB disease prior
to the development of cognitive or motor symptoms.
DLB is differentiated from PDD on the basis that cogni-
tive features develop before or within a year of parkin-
sonism. In the move toward earlier diagnosis, the
identification of slight parkinsonian signs and mild cog-
nitive difficulties prior to the development of any full
clinical syndrome makes such distinctions more difficult.
The distinction between DLB and PDD is unlikely to be
useful or practicable at this stage and a general classifi-
cation of ‘prodromal LB disease’ may be more appropri-
ate. Different patterns of biomarkers may possibly
emerge as predictors of which patients will progress to
develop particular clinical presentations over time.
At present, in the absence of disease-modifying ther-
apies, identifying LB disease prior to the development of
cognitive or motor dysfunction has little obvious clinical
benefit. However, enquiring about prodromal symptoms
may be most helpful in current clinical practice when
the clinician is endeavouring to establish the cause of
dementia in a patient who already has mild, moderate or
even severe impairment but in whom the subtype diag-
nosis remains unclear. Enquiry about prodromal symp-
toms, particularly but not restricted to RBD, can be
extremely informative in signposting a DLB diagnosis
that can be further substantiated with use of a biomarker
appropriate to that stage of disease.
Conclusions
There is a growing belief that by the time dementia has
developed, sufficient brain damage has occurred to pre-
vent any disease-modifying treatment working effect-
ively. The identification of prodromal dementia allows
researchers to investigate the initial phases of dementia
pathophysiology, develop treatments designed to inter-
rupt the development of the dementia syndrome and ac-
curately identify the patients most likely to benefit from
these treatments.
Prior to the availability of such treatments, it is not clear
that a clinical diagnosis of prodromal dementia is useful to
patients or their clinicians [85]. The European Union Joint
Action on Alzheimer’s Initiative recently provided recom-
mendations on the timely diagnosis of dementia [86].
Timely diagnosis here reflects ‘access to diagnosis at a
time when people can use this information to make sense
of what is happening to them, make lifestyle changes and
plan for the future’ [86]. Timely diagnosis may thuschange when new information or treatments become
available. At present, diagnosis of DLB in the early stages
of dementia would seem more timely and appropriate
than an earlier diagnosis of prodromal LB disease of un-
certain prognosis. That said, knowledge of the prodromal
development of DLB could help clinicians identify cases of
DLB where the diagnosis is uncertain.
For the DLB research community, the diagnosis of
prodromal DLB is an area of growing interest, providing
an important opportunity to investigate the earliest
stages of LB disorders. Such efforts are already underway
in RBD [82] and prospective cohorts based upon other
risk profiles need to be similarly studied.
Further characterisation of biomarkers confirming the
presence of LB pathology has been identified as a prior-
ity for LB disease research [87] and is a necessary pre-
requisite for conducting clinical trials of emerging
prevention agents. The widespread deposition of αSyn
pathology in DLB may prove key in prodromal diagnosis.
Based on current evidence and the temporal develop-
ment of LB pathology, some of the most promising early
biological markers include 123I-MIBG cardiac scintig-
raphy, skin biopsy and measures of substantia nigra
pathology. Over the coming years, longitudinal studies
should establish which of these markers are most effect-
ive. In parallel with this, such studies will help to un-
cover the early pathophysiology of LB disease, aiding the
development of treatment and prevention strategies.Abbreviations
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